Lenvatinib in Combination With Carboplatin Pemetrexed & Pembrolizumab for

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04122833` - Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Recruiting	`NCT04989322` - Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC	Phase 2
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2
Recruiting	`NCT04425681` - Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer	Phase 2
Enrolling by invitation	`NCT05136014` - Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
Not yet recruiting	`NCT04148898` - Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis	Phase 2
Active, not recruiting	`NCT05241873` - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Not yet recruiting	`NCT05778149` - Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation	Phase 2
Recruiting	`NCT05768490` - Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases	Phase 3
Terminated	`NCT02949843` - Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Phase 2
Completed	`NCT04764214` - SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs	Phase 2
Recruiting	`NCT05382728` - Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)	Phase 3
Recruiting	`NCT05244213` - Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC	Phase 2
Active, not recruiting	`NCT04862780` - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Phase 1/Phase 2
Terminated	`NCT02846792` - Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT04944069` - Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis	N/A
Recruiting	`NCT05257967` - CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease	N/A
Active, not recruiting	`NCT04233021` - Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation	Phase 2
Not yet recruiting	`NCT04470076` - Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation	Phase 2

NCT number	NCT05258279
Study type	Interventional
Source	Juntendo University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 1, 2022
Completion date	October 2024

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms